Preclinical data consistently demonstrated that SPMs modulate key inflammatory pathways, support epithelial repair, and help restore immune balance. Human studies revealed altered cutaneous and systemic lipid mediator profiles-characterized by reduced omega-3-derived SPMs and predominance of omega-6-driven inflammatory mediators-suggesting impaired resolution mechanisms across these disorders. Interventional studies showed that omega-3 supplementation may reduce inflammatory markers, improve barrier function, and alleviate clinical symptoms.
Relevant if you experience acne and sensitivity.
If you're targeting acne, this research adds to the evidence base, look at the key findings for the mechanism the study describes.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
1. Antioxidants (Basel). 2025 Dec 21;15(1):9. doi: 10.3390/antiox15010009. Specialized Pro-Resolving Lipid Mediators and Dietary Omega-3/6 Fatty Acids in Selected Inflammatory Skin Diseases: A Systematic Review. Biełach-Bazyluk A(1), Jakubowicz-Zalewska O(1), Myśliwiec H(1), Flisiak I(1).
1. Antioxidants (Basel). 2025 Dec 21;15(1):9. doi: 10.3390/antiox15010009. Specialized Pro-Resolving Lipid Mediators and Dietary Omega-3/6 Fatty Acids in Selected Inflammatory Skin Diseases: A Systematic Review. Biełach-Bazyluk A(1), Jakubowicz-Zalewska O(1), Myśliwiec H(1), Flisiak I(1). Author information: (1)Department of Dermatology and Venereology, Medical University of Bialystok, 15-540 Bialystok, Poland. Specialized pro-resolving mediators (SPMs), including lipoxins, resolvins, protectins, and maresins, actively terminate inflammation and restore tissue homeostasis. This review addresses how specialized pro-resolving mediators (SPMs) and their omega-3/omega-6 PUFA precursors influence inflammatory pathways, disease mechanisms, and therapeutic potential across major inflammatory skin disorders. MEDLINE/PubMed was searched on 4 October 2025. Eligible studies included experimental, animal, mechanistic human, and interventional research examining SPMs or omega-3/omega-6 fatty acids. Non-English articles, reviews, conference abstracts, and dietary questionnaire-only studies were excluded. Two reviewers independently screened and extracted data. Due to heterogeneity, a narrative synthesis was performed. No formal risk-of-bias assessment was undertaken Of 359 records, 57 studies were included (26 psoriasis, 24 atopic dermatitis, 7 acne; scarce hidradenitis suppurativa data). Preclinical data consistently demonstrated that SPMs modulate key inflammatory pathways, support epithelial repair, and help restore immune balance. Human studies revealed altered cutaneous and systemic lipid mediator profiles-characterized by reduced omega-3-derived SPMs and predominance of omega-6-driven inflammatory mediators-suggesting impaired resolution mechanisms across these disorders. Interventional studies showed that omega-3 supplementation may reduce inflammatory markers, improve barrier function, and alleviate clinical symptoms. Early evidence on SPMs analogues and receptor agonists indicates promising therapeutic potential, but clinical data remain sparse. The body of evidence is limited by scarce human data, small sample sizes, heterogeneous interventions and variable methods. Many studies rely on subjective or non-standardized clinical outcomes, and the predominance of experimental models further limits the translational relevance of current findings. In summary, disturbances in PUFA-derived lipid mediator pathways and insufficient activation of pro-resolving mechanisms may contribute to the persistence of cutaneous inflammation. Omega-3 supplementation and SPMs-based novel therapies therefore represent plausible adjunctive approaches; however, their therapeutic relevance requires confirmation in future mechanistic and clinical studies. DOI: 10.3390/antiox15010009 PMCID: PMC12837189 PMID: 41596068 Conflict of interest statement: The authors declare no conflicts of interest.
Original source →Wounds continue to represent a significant public health challenge globally. In recent years, Astragalus mongholicus Bunge, a traditional Chinese botanical drug utilized for wound treatment, has garnered increasing research attention. However, the therapeutic efficacy and safety of this natural botanical drug on wound healing remain poorly understood.
This study evaluated the safety and effectiveness of HYDRAGEL A2, an injectable medical device containing hyaluronic acid (HA), polynucleotides (PN), and niacinamide, for improving facial skin quality. These ingredients are increasingly recognized for their synergistic effects in aesthetic medicine, with HA and PN providing hydration and skin support, and niacinamide offering anti-inflammatory and antioxidant properties. A prospective, open-label clinical investigation was conducted on 42 female subjects (mean age 45 ± 1 years, Fitzpatrick skin phototypes II-V) to assess skin elasticity, hydration, and mild skin depression correction following cheek area injections.
Sensitive skin syndrome (SSS) is a common self-reported condition, more prevalent in women, characterized by redness, irritation, and discomfort in response to various triggers. SSS remains a multifactorial condition with overlapping symptoms and no clear correlation between sensory complaints and observable signs, complicating both diagnosis and management. This study aimed to establish expert-driven recommendations for the diagnosis, treatment, and holistic care of SSS.
This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →